Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of AZD6738 in Combination With Durvalumab (MEDI4736), in Patients With Metastatic Solid Tumor as Salvage Treatment

NCT03780608 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT03780608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03780608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of AZD6738 in Combination With Durvalumab (MEDI4736), in Patients With Metastatic Solid Tumor as Salvage Treatment
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
July 30, 2019
Completion date
December 1, 2023
Enrollment
61 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, malignant melanoma